Prophylactic treatment with Hugan tablets for antituberculosis drug-induced liver injury:A systematic review and meta-analysis of randomized controlled trials
Objective:Antituberculosis drug-induced liver injury(anti-TB DILI)is a common adverse effect in patients undergoing anti-TB treatment.Hugan tablets(HGT),a traditional Chinese patent medicine,are widely used to treat and prevent DILI in China.However,their prophylactic effects on anti-TB DILI remain largely unknown.The aim of the present study was to evaluate the efficacy and safety of prophylactic therapy with HGT for anti-TB DILI.Methods:Six major Chinese and English databases were searched from the date of their inception to December 2021 without restrictions on language and publication bias.Qualifying studies were selected independently by two authors based on the inclusion and exclusion criteria,after which the data were extracted and a meta-analysis was conducted.Results:A total of 4 270 patients from 18 studies were included in the present systematic review and meta-analysis.The results revealed that HGT was associated with a significant reduction in the occurrence of anti-TB DILI[RR =0.29,95%CI(0.24,0.36),P<0.05].Sensitivity analysis indicated that the results were stable.HGT administration was associated with a significant reduction in the occurrence of anti-TB DILI within-[RR =0.27,95%CI(0.16,0.48),P<0.001]and after four weeks[RR = 0.34,95%CI(0.17,0.66),P = 0.001],with low heterogeneity.The incidence of anti-TB DILI in patients with Hepatitis B surface antigen positive(HBsAg +)was also significantly reduced[R =0.25,95%CI(0.15,0.39),P<0.001].Conclusion:We found that prophylactic treatment with HGT apparently positively affects anti-TB DILI,especially in HBsAg + patients.More high-quality studies are needed to further investigate its efficacy and safety.
NETL
NSTL
万方数据
维普
